Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Invested Capital (2016 - 2025)

Historic Invested Capital for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $87.8 million.

  • Coherus Oncology's Invested Capital rose 21142.93% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year increase of 21142.93%. This contributed to the annual value of -$118.4 million for FY2024, which is 3774.1% up from last year.
  • Latest data reveals that Coherus Oncology reported Invested Capital of $87.8 million as of Q3 2025, which was up 21142.93% from $119.8 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Invested Capital peaked at $386.2 million during Q2 2021, and registered a low of -$196.3 million during Q1 2023.
  • For the 5-year period, Coherus Oncology's Invested Capital averaged around -$14.0 million, with its median value being -$78.8 million (2024).
  • As far as peak fluctuations go, Coherus Oncology's Invested Capital tumbled by 166284.33% in 2023, and later surged by 25996.98% in 2025.
  • Over the past 5 years, Coherus Oncology's Invested Capital (Quarter) stood at $97.7 million in 2021, then crashed by 240.62% to -$137.4 million in 2022, then crashed by 38.36% to -$190.1 million in 2023, then soared by 37.74% to -$118.4 million in 2024, then skyrocketed by 174.15% to $87.8 million in 2025.
  • Its Invested Capital was $87.8 million in Q3 2025, compared to $119.8 million in Q2 2025 and -$157.2 million in Q1 2025.